Table I MRM parameters and analytical precision of MRM assays based on proteotypic tryptic peptides for 45 plasma proteins

Masses listed are for the natural forms all 45 peptides. MRM parameters are sorted by decreasing fragment ion intensity. HC, heavy chain; CVD, cardiovascular disease.

ProteinUniProt accession no.Peptide sequencePeptide molecular massQ1aQ3bDPCEFragment ionCVc-Fold signal increasedPutative disease associationRefs.
DaVV%
AfaminP43652DADPDTFFAK1125.5563.8825.46024y75.411.1Ovarian cancer30
563.8413.26023y72+6.1
563.8940.46027y86.9
Albumin, serumP02768LVNEVTEFAK1148.6575.3185.27032a21.4CVD18
575.3937.57025y81.44.5
575.3213.27027b21.1
α1-Acid glycoprotein 1P02763NWGLSVYADKPETTK1707.8570.3704.95624y132+2.214.0CVD, cervical cancers18, 38
570.3273.15630a23.6
570.3301.15625b26.0
α1-AntichymotrypsinP01011EIGELYLPK1060.6531.3244.26031y24.1CVD, Alzheimer disease18, 27
531.3819.56024y73.528.2
531.3215.16031a22.5
α1B-GlycoproteinP04217LETPDFQLFK1236.6619.3243.16531b22.0Pancreatic, liver and bladder cancers34, 41, 43
619.3894.56528y71.52.5
619.3215.16535a21.9
α2-AntiplasminP08697LGNQEPGGQTALK1311.7656.8771.48233y82.61.2CVD18
656.8542.38231b53.0
656.8900.58233y96.2
α2-MacroglobulinP01023LLIYAVLPTGDVIGDSAK1844.0615.7586.85817y122+2.219.1CVD18
615.7673.45817b61.7
615.7530.35824y112+2.9
AngiotensinogenP01019ALQDQLVLVAAK1267.8634.9542.87325y102+5.13.7CVD18
634.9956.67329y95.7
634.9289.27329y35.1
Antithrombin-IIIP01008DDLYVSDAFHK1308.6437.2540.34717y92+4.77.6CVD18
437.2483.74718y82+4.8
437.2704.34723y66.9
Apolipoprotein A-IP02647ATEHLSTLSEK1214.6405.9572.85219y102+1.1CVD18
405.9522.35218y92+1.78.4
405.9363.25224y31.4
Apolipoprotein A-II precursorP02652SPELQAEAK971.5486.8443.26426y82+5.71.6CVD, prostate cancer18, 36
486.8157.16434a2N.D.
486.8788.46425y70.9
Apolipoprotein A-IVP06727SLAPYAQDTQEK1349.7675.8540.36730y92+2.76.6CVD18
675.8575.86730y102+5.7
675.81079.56730y94.5
Apolipoprotein B-100P04114FPEVDVLTK1046.6524.3450.86528y82+2.95.4Coronary heart disease40
524.3803.56526y74.4
524.3674.46532y68.9
Apolipoprotein C-I lipoproteinP02654TPDVSSALDK1031.5516.8466.27829y92+2.58.9CVD18
516.8834.47829y83.0
516.8620.37829y62.3
Apolipoprotein C-IIIP02656GWVTDGFSSLK1195.6598.8244.15931b21.1CVD18
598.8854.45926y81.94.5
598.8953.55925y92.5
Apolipoprotein EP02649LGPLVEQGR967.6484.8399.77025y72+3.611.0CVD18
484.8588.37030y53.8
484.8489.27028y44.3
β2-Glycoprotein IP02749ATVVYQGER1021.5511.8652.36525y51.6CVD18
511.8751.46525y61.63.2
511.8850.46525y71.9
CeruloplasminP00450EYTDASFTNR1202.5602.3624.36629y56.01.4CVD18
602.3911.46629y46.0
602.3695.46632y65.2
ClusterinP10909ELDESLQVAER1287.6644.8375.27530y35.7CVD18
644.8802.47533y76.7
644.8602.37531y55.12.2
Coagulation factor XIIa HCP00748VVGGLVALR882.6442.3685.46021y72.615.4CVD18
442.3171.16025a24.9
442.3199.16021b23.9
Complement C3P01024TGLQEVEVK1001.5501.8731.46525y63.01.8CVD18
501.8603.36526y51.7
501.8422.76525y72+6.4
Complement C4 β chainP0C0L5VGDTLNLNLR1113.6557.8629.47031y56.91.1CVD, renal carcinoma18, 38
557.8742.57030y65.4
557.81015.57032y97.2
Complement C4 γ chainP0C0L5ITQVLHFTK1085.6362.9487.38816y82+3.75.3CVD, renal carcinoma18, 30
362.9436.88815y72+6.3
362.9215.18818b210.1
Complement component C9P02748TEHYEEQIEAFK1522.7508.6494.36623y411.33.6
508.6607.36621y511.8
508.6917.46619b715.6
Complement factor BP00751EELLPAQDIK1154.6578.3671.46525y62.318.5
578.3372.26529b33.8
578.3259.16539b25.5
Complement factor HP08603SPDVINGSPISQK1340.7671.4830.47735y87.52.4Acute macular degeneration32
671.4943.57735y96.8
671.4399.27737b47.1
Fibrinogen α chainP02671GSESGIFTNTK1139.6570.8610.36126y52.21.5CVD, oral cancer18, 26
570.8867.56128y83.3
570.8780.46125y73.0
Fibrinogen β chainP02675QGFGNVATNTDGK1307.6654.8706.38534y72.41.3CVD, gastrointestinal stromal tumor18, 31
654.8635.38534y62.1
654.8805.48534y82.7
Fibrinogen γ chainP02679DTVQIHDITGK1225.6409.6505.84917y92+2.98.1CVD, Alzheimer disease18, 35
409.6189.14922a26.2
409.6217.14919b28.4
Gelsolin, isoform 1P06396TGAQELLR886.5444.3159.17028b24.9Progression to breast carcinoma42
444.3530.37025y45.41.2
444.3658.47025y56.3
Haptoglobin β chainP00738VGYVSGWGR979.5490.8562.36125y51.72.6CVD18
490.8320.26125b31.7
490.8661.36125y61.9
HemopexinP02790NFPSPVDAAFR1219.6610.8480.35925y92+0.83.1CVD18
610.8234.15933a21.1
610.8959.55926y91.3
Heparin cofactor IIP05546TLEAQLTPR1027.6514.8814.46525y76.07.8CVD18
514.8685.46527y65.8
514.8373.26525y36.9
Inter-α-trypsin inhibitor HCP19827AAISGENAGLVR1156.6579.3902.56628y93.510.3
579.3815.46630y84.2
579.3508.36626y102+3.1
Kininogen-1P01042TVGSDTFYSFK1250.6626.3173.16240a22.7Colorectal cancer39
626.31051.56226y92.833.0
626.3201.16229b22.6
L-selectinP14151AEIEYLEK993.5497.8794.46421y612.46.0CVD18
497.8201.16423b210.1
497.8173.16429a219.6
Plasma retinol-binding proteinP02753YWGVASFLQK1197.6599.8849.57628y85.8Lung cancer37
599.8350.27627b23.7
599.8693.47629y63.75.5
PlasminogenP00747LFLEPTR874.5438.3615.35221y52.65.5CVD18
438.3233.25225a23.9
438.3261.25222b23.4
ProthrombinP00734ETAASLLQAGYK1250.7626.3679.47029y65.5CVD18
626.3879.57029y87.13.9
626.3792.57029y74.3
Serum amyloid P-componentP02743VGEYSLYIGR1155.6578.8708.48027y66.63.2Renal cancer38
578.8508.38029y47.2
578.8871.58027y78.5
TransferrinP02787EDPQTFYYAVAVVK1628.8815.4693.47534y122+1.068.7CVD, early ovarian cancer33
815.4912.57533y81.3
815.41059.67538y92.3
TransthyretinP02766AADDTWEPFASGK1393.6697.8606.37038y61.992.9Ovarian cancer38
697.8921.57032y82.7
697.8735.47031y74.0
Vitamin D-binding proteinP02774THLPEVFLSK1169.6390.9494.34417y43.512.7Prostate cancer29
390.9578.34417b53.6
390.9352.24425b34.8
VitronectinP04004FEDGVLDPDYPR1421.7711.8875.47531y73.2CVD18
711.8647.37542y53.65.8
711.8762.37532y64.2
Zinc-α2-glycoproteinP25311EIPAWVPFDPAAQITK1781.9892.01087.65540y103.5Prostate cancer28
892.0770.95535y142+3.748.1
892.0696.45534b64.4
  • a Endogenous peptide precursor m/z.

  • b Fragment ion m/z.

  • c Determined as 1 S.D. proportional to the mean.

  • d Intensity of optimized MRM Q1/Q3 pairs versus intensity of in silico predicted MRM Q1/Q3 ion pairs using the first y fragment ion m/z that is greater than the precursor ion m/z with a CE voltage calculated using CE = m/z × 0.05 + 5.